Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AOP Health, VRG Therapeutics Unite to Advance Inflammation and Immunology Target | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

AOP Health, VRG Therapeutics Unite to Advance Inflammation and Immunology Target

The novel Kv1.3 potassium channel inhibitor is a key regulator of immune cell activity.

Author Image

By: Patrick Lavery

Content Marketing Editor

AOP Health and VRG Therapeutics are partnering on a novel Kv1.3 potassium channel inhibitor for inflammation and immunology (I&I) indications.

AOP is a global pharmaceutical enterprise group that focuses on integrated therapies for rare diseases and critical care. VRG, meanwhile, is a Budapest-based AI-driven developer of miniproteins.

Addressing Inflammation and Immunology Needs

It is the field of miniproteins on which this strategic partnership will center. VRG’s AI-MPRO program—combining AI-driven protein design with experimental validation—discovered a next-generation miniprotein candidate.

The focus is now on generating additional, preclinical proof-of-concept data to progress toward first-in-human studies.

As for Kv1.3, a clinically validated target, it plays a critical role in regulating pathogenic immune cells. This applies to chronic inflammatory or autoimmune disorders. Selectively inhibiting Kv1.3 can modulate immune responses driving disease, while minimizing side effects.

Previous limitations to advancements that targeted Kv1.3 might be overcome, however. This is due to the “exceptional” selectivity and precision of the miniprotein modality.

What AOP and VRG Get From the Deal

Through this collaboration, AOP is expanding its external R&D into complex and scientifically active areas. Concurrently, VRG has an opportunity to validate the AI-MPRO platform, advancing its technology toward clinical application.

“[The] platform has demonstrated the ability to generate highly selective candidates against complex biological targets,” said AOP CEO Martin Steinhart. “We see strong potential in targeting Kv1.3 for autoimmune and inflammatory diseases and look forward to advancing this program.”

“AOP Health is an ideal partner for this program,” Zalán Péterfi, VRG Chairman of the Board and Managing Director, said. “Advancing together the Kv1.3 program, we intend to expand our partnership to fully exploit the platform potential.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics